


## Development of an Intein-Inspired Amide Cleavage Chemical Device

Chiaki Komiya,<sup>†</sup> Keisuke Aihara,<sup>†</sup> Ko Morishita, Hao Ding, Tsubasa Inokuma, Akira Shigenaga, and Akira Otaka\*

Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences, Tokushima University, Tokushima 770-8505, Japan

### Supporting Information

**ABSTRACT:** A photoresponsive amide cleavage device was developed based on the asparagine imidation-mediated cleavage of peptide bonds during intein-mediated protein splicing. The chemical environment of the protein splicing process was mimicked by the incorporation of geminal dimethyl groups and a secondary amine unit in asparagine scaffold. Furthermore, the resulting photoresponsive device could induce the phototriggered cleavage of an amide bond by the protection of the secondary amine unit with an *o*-nitrobenzyloxycarbonyl group.



Intein proteins,<sup>1</sup> which are found in a wide range of unicellular organisms,<sup>2</sup> mediate the self-splicing of intein-containing proteins to produce intein-removed splicing proteins through sequential *N*–*S*(or *O*)-, *S*(or *O*)–*S*(or *O*)-, and *S*(or *O*)–*N*-acyl transfers. The third *S*(or *O*)–*N*-acyl-transfer step in this process starts from the imide cyclization of an asparagine (Asn) residue at the intein C-terminus, which is followed by the transfer of an *O*(or *S*)–peptidyl unit to the liberated amino group.<sup>3</sup> The progress of this sequence of reactions depends on several requirements, including (i) enhancement of the nucleophilicity of the amide side chain of the Asn residue; (ii) activation of the scission peptide bond; and (iii) appropriate arrangement of the functional groups involved in the reactions. An analysis of the structural basis for this reaction<sup>4</sup> indicated that the appropriate arrangement of several functional units, including a water molecule, assist in the cleavage of the amide via an acid–base-catalyzed mechanism (Figure 1).<sup>4a</sup>




Figure 1. Mechanism of acid–base-catalyzed amide cleavage.

Methodologies for photoinduced amide bond cleavage<sup>5</sup> and conformational change<sup>6</sup> have provided powerful tools for the spatiotemporal control of the functions of peptide/proteins. We previously developed a stimulus-responsive processing residue (Spr)<sup>7</sup> based on a trimethyl-lock system.<sup>8,9</sup> This Spr system has shown utility in the field of chemical biology and has potential for real-life application.<sup>7a,c,e</sup> In conjunction with our studies on Spr, we also explored the development of an alter-

native new scaffold. In this context, the result of a mechanistic study<sup>4</sup> of the third step of the reaction mentioned above inspired us to design a new amide bond cleavage device with a modified Asn structure. In this way, it was envisioned that the modifications shown in Figure 2 would provide the structural





Figure 2. Design of an intein-mediated UV-responsive amide-cleavage device.

features necessary to affect the cleavage of an amide bond. The incorporation of a pendant secondary amine would provide an intramolecular base,<sup>10</sup> which could enhance the nucleophilicity of the amide nitrogen. Furthermore, the incorporation of geminal dimethyl groups would lead to a Thorpe–Ingold effect,<sup>11–13</sup> which would fix the conformation of the intein system and assist in the formation of the succinimide ring. Lastly, the masking of the basic character of the secondary amine with a photosensitive *N*-protecting group,<sup>14</sup> such as *o*-nitrobenzyloxycarbonyl (*o*-NBoc), could provide a simple platform for the development of stimulus-responsive amide bond cleavage device.

Our work toward preparation of a pendant secondary amine capable of responding to UV irradiation started from

Received: October 16, 2015

Published: December 8, 2015


Scheme 1. Synthesis of the Pendant Secondary Amine 4a and 4b<sup>a</sup>

<sup>a</sup>Reagents and conditions: (i)  $\text{Boc}_2\text{O}$ , THF; (ii) **2**,  $\text{Et}_3\text{N}$ , THF, quant (two steps); (iii) TFA,  $\text{CH}_2\text{Cl}_2$ ; (iv) ethyl trifluoroacetate,  $\text{CH}_2\text{Cl}_2$ ; (v)  $\text{Boc}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$ ; (vi)  $\text{K}_2\text{CO}_3$ , MeOH,  $\text{H}_2\text{O}$ .

*N*-ethylethylenediamine (**1**) (Scheme 1). The reaction of **1** with *tert*-butyloxycarbonyl anhydride ( $\text{Boc}_2\text{O}$ ) in THF allowed for the selective protection of the primary amino group. The subsequent reaction of the secondary amino group with *p*-nitroformate **2**<sup>15</sup> and triethylamine ( $\text{Et}_3\text{N}$ ) in THF afforded the requisite compound **3** in quantitative yield (over two steps). The trifluoroacetic acid (TFA)-mediated removal of the Boc protecting group from **3** gave the pendant amine unit **4a**. The synthesis of the Boc-protected pendant unit **4b** proceeded via the trifluoroacetylation of the primary amino group of **1** followed by the introduction of a Boc group and the subsequent hydrolysis of the trifluoroacetyl protecting group.


PhFI-diMe-Asp(OMe)-OMe (**5**)<sup>16</sup> was synthesized over three steps from *L*-aspartic acid (**6**) following Goodman's procedure (Scheme 2). The deprotection of the PhFI group in **5** with a mixture of TFA and triethylsilane (TES) in  $\text{CH}_2\text{Cl}_2$  followed by the protection of the resulting amine with allylchloroformate (Alloc-Cl) gave Alloc-diMe-Asp(OMe)-OMe (**7**). The subsequent hydrolysis of the two methyl esters of **7** with LiOH in a mixture of THF and  $\text{H}_2\text{O}$  gave the corresponding carboxylic acid, which was reacted with  $\text{Ac}_2\text{O}$  in THF at reflux temperature, followed by an alcoholysis reaction with allyl alcohol to give the  $\alpha$ -allyl ester Alloc-diMe-Asp(OH)-OAllyl **8** in 60% isolated yield (over five steps). The reaction of the UV-responsive amine **4a** with the sterically crowded  $\beta$ -carboxylic acid of **8** was accomplished using bromotripyrrolidinophosphonium hexafluorophosphate (PyBrop) and diisopropylethylamine (DIPEA) in  $\text{CH}_2\text{Cl}_2$  to yield the fully protected Asn derivative Alloc-diMe-Asn(Et-*N*-*o*NBnoc)-OAllyl **9a** in 75% isolated yield. The conversion of **9a** to the corresponding 9-fluorenylmethoxycarbonyl (Fmoc)-protected derivative for Fmoc solid-phase peptide synthesis (SPPS) was achieved by the deprotection of the allyl and allyloxycarbonyl (Alloc) groups by the treatment of **9a** with  $\text{Pd}(\text{PPh})_4$  and *N*-methylaniline, followed by the Fmoc protection of the resulting amine to give Fmoc-diMe-Asn(Et-*N*-*o*NBnoc)-OH **10a** in 92% isolated yield. The Boc-protected material Fmoc-diMe-Asn(Et-*N*-Boc)-OH **10b** was also prepared in a similar manner in 70% isolated yield from **9b**.

With the requisite Asn derivatives in hand, we proceeded to synthesize two model peptides (H-YGGFL-X-SGFLYGF-NH<sub>2</sub>, **11a** and **11b**; X = Asn derivatives) to examine the self-processing properties of the peptides. The Fmoc-protected amino acids were condensed on NovaSyn TGR resin using diisopropylcarbodiimide (DIPCDI) and 1-hydroxybenzotriazole (HOBt) in dimethylformamide (DMF) except for **10a** and **10b**. The condensation of compound **10a** was achieved using 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5- $\beta$ ]pyridine

Scheme 2. (a) Synthesis of the Intein-Inspired Amide Cleavage Device 10a and 10b and (b) Preparation of a Model Peptide<sup>a</sup>

<sup>a</sup>Reagents and conditions: (i) TFA, TES,  $\text{CH}_2\text{Cl}_2$ ; (ii) AllocCl,  $\text{NaHCO}_3$ , THF,  $\text{H}_2\text{O}$ ; (iii) LiOH, THF,  $\text{H}_2\text{O}$ ; (iv)  $\text{Ac}_2\text{O}$ , THF; (v) allyl alcohol, 60% (five steps); (vi) **4a** or **4b**, PyBrop, DIEA,  $\text{CH}_2\text{Cl}_2$ ; (vii)  $\text{Pd}(\text{PPh})_4$ , *N*-methylaniline, THF then FmocOSu, DIPEA


3-oxide hexafluorophosphate (HATU) and DIEA in *N*-methylpyrrolidone (NMP). The completed peptide resins were subsequently exposed to a mixture of TFA–ethanedithiol (EDT)–*m*-cresol–thioanisole– $\text{H}_2\text{O}$  at room temperature for 2 h to give a mixture of two peptides with mass values identical to that of the desired material (Figure 3).

Figure 3. Possible mechanism for the generation of byproduct **18**.

The origin of the two peptides was attributed to the formation of the succinimide species **12** during the activation of **10a**, followed by the aminolysis of the succinimide ring by the amino group of the growing peptide chain. Given that one of the two possible electrophilic sites in the succinimide ring of **12**

was sterically crowded by the neighboring geminal dimethyl groups, it was anticipated that the major product of this reaction would be desired  $\alpha$ -peptide **11a**. We envisaged that the benzyl protection of the amide nitrogen in **10a** would prevent the formation of the succinimide ring.<sup>17</sup> However, our attempts to synthesize the dimethoxybenzyl (DMB)-protected Asn derivative **13** resulted in failure (Scheme 3). Although the

### Scheme 3. Synthetic Approach to **13** and the Synthesis of the Isomeric Peptide **18**<sup>a</sup>



<sup>a</sup>Reagents and conditions: (i) 2,4-dimethoxybenzaldehyde, Na<sub>2</sub>SO<sub>4</sub>, MeOH; NaBH<sub>4</sub>; (ii) MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub> then **14a**, 50%; (iii) MsCl, Et<sub>3</sub>N, THF then **14a**, 60%; (iv) Pd(PPh<sub>3</sub>)<sub>4</sub>, *N*-methylaniline, THF then FmocOSu, DIPEA, quant.

condensation of the *N*-dimethoxybenzylidiamine derivative **14a** with **8** gave the desired amide **15** in 50% yield, the subsequent exchange of the protecting groups resulted in the release of the pendant amine molecule **14a**. The failure of this reaction was attributed to the nucleophilic attack of the  $\alpha$ -carboxylate on the substituted amide. To confirm the structure of peptide **18** as the isopeptide form, the  $\alpha$ -amide-protected derivative **16**, suitable for the straightforward preparation of **18**, was prepared from the reaction of the  $\beta$ -allyl ester **17** with **14a** (Scheme 3).

The resulting imidation-tolerant  $\beta$ -carboxylic derivative **16** was also incorporated into a peptide resin in a manner similar to that employed for **11a**. The subsequent deprotection of the resin afforded the  $\beta$ -peptide **18**. This result clearly indicated that the major and minor products of the succinimide ring-opening reaction described above were **11a** and **18**, respectively. This result is shown in the HPLC chart in Figure 3 for the  $\alpha$ - and  $\beta$ -peptides, respectively. A peptide sample without a UV-responsive group was also synthesized using the Boc-protected secondary amine **10b** in a manner similar to that used for **11a**. This peptide behaved in the same way as the corresponding system containing **10a**, in that the deprotection of the protected resin afforded a mixture of  $\alpha$ - and  $\beta$ -peptides.

Peptides **19** and **20** were also prepared to determine the effects of the geminal dimethyl groups and secondary amine on the outcome of the transformation.<sup>18</sup> The Asn-protected derivative without geminal dimethyl groups was prepared by the coupling of the  $\beta$ -carboxylic acid of Fmoc-Asp(OH)-OAllyl<sup>19</sup> with *N*-DMB-*N'*-Boc-*N'*-ethylethylenediamine **14b**, followed by the removal of the allyl ester. The Fmoc-based incorporation of the resulting amino acid into the resin was followed by an acidic deprotection step to afford the desired peptide **19**, where the Asn residue had been successfully

modified with a pendant secondary amine without the need for the protection of the secondary amine. Notably, no significant side reactions, including the hydrolysis of the peptide bonds, were observed during the acidic deprotection and HPLC purification stages. The Asn-incorporated peptide **20** was also synthesized as a separate reference compound using standard Fmoc protocols.

We initially investigated the self-processing of these synthetic peptides, as shown in Figure 4. Peptide samples were dissolved





Figure 4. Self-processing reactions of the model peptides. \*Internal standard.

in a buffered solution (6 M guanidine hydrochloride (Gn-HCl)-0.2 M phosphate), where they were monitored for peptide bond cleavage by HPLC analysis. As expected, the presence of both the secondary amine as an intramolecular base and the geminal methyl groups as an inducer of cyclization greatly facilitated the cleavage of the peptide bond (Figure 4, entries 1–3). When a mixture of the materials was held at pH 7.4 for 24 h at 37 °C, almost all of the samples went to completion to afford a mixture of split peptides consisting of *N*-half imide peptide **21**, *C*-half peptide **22**, and the succinimide ring-opened peptides **23** and **24**. The results of these comparison experiments clearly show that modifications capable of mimicking the environments involved in the intein-induced cleavage of an amide bond were responsible for the envisioned artificial amide bond cleavage reaction (Figure 4, entry 4).

Encouraged by the potential utility of **10a** as a stimulus-responsive processing device, we next examined the photo-responsive cleavage of the peptide bond in the synthetic peptide **11a** (Figure 5). When the *o*-NBoc-protected peptide





**Figure 5.** Photoresponsive peptide bond cleavage. \*Internal standard. \*\*Not peptidyl compounds, probably derived from deprotected *o*-NBnoc group with UV irradiation.

**11a** was incubated for 24 h at 37 °C in a mixture of 6 M Gn·HCl and 0.2 M phosphate at pH 7.4 without UV irradiation, the material remained almost completely intact. The irradiation of the reaction mixture with UV light led to the removal of the *o*NBnoc group from the secondary amine unit to produce peptide **11b**, which was split to the processing peptides with about 80% cleavage after 24 h. These results clearly indicated that **11a** could serve as a stimulus-responsive processing device and an alternative to the Spr system based on a trimethyl lock.

In conclusion, we achieved the development of the new amide bond cleavage device modeled on the intein-mediated protein splicing. The design concept of the device is derived from the mimicking chemical environments involved in the protein splicing. Although preparation of the device and its incorporation into peptides are laborious, an important issue in this work is that the incorporation of geminal dimethyl groups and a secondary amine unit in asparagine scaffold imitate the splicing system. Furthermore, protection of the secondary amine with the photoremoval group allowed the device to cleave the amide bond in response to photoirradiation.

## EXPERIMENTAL SECTION

**General Information.** All reactions were carried out under an atmosphere of argon. All commercial reagents were used without further purification. For column chromatography, silica gel (spherical, natural, 63–210 μm) was used. The progress of reactions was monitored by thin-layer chromatography using precoated silica gel glass plates (0.25 mm) with F254 indicator. Mass spectra (ESI-MS) were obtained using a ToF mass spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were measured using a 300 or 400 MHz spectrometer at room temperature unless otherwise noted. Chemical shifts were calibrated to the solvent signal. Multiplicities are given as s (singlet), d (doublet), br d (broad doublet), t (triplet), br t (broad triplet), q (quartet), m (multiplet), or br m (broad multiplet). For HPLC separation, a Cosmosil 5C<sub>18</sub>-AR-II analytical column (4.6 × 250 mm, flow rate 1.0 mL/min) or a Cosmosil 5C<sub>18</sub>-AR-II semipreparative column (10 × 250 mm, flow rate 3.0 mL/min) was employed, and eluting products were detected by UV at 220 nm. A solvent system consisting of 0.1% TFA aqueous solution (v/v, solvent A) and 0.1% TFA in

MeCN (v/v, solvent B) was used for HPLC elution. IR spectra and optical rotations were measured using a polarimeter (concentration in g/100 mL), respectively. Photolysis was performed with the filtered output (>365 nm) of a 3000 mW/cm<sup>2</sup> HG-Xe lamp.

**Synthesis of Asparagine Derivatives.** *2-Nitrobenzyl [2-[(tert-Butoxycarbonyl)amino]ethyl]ethyl Carbamate (3)*. To a solution of *N*-ethylethylenediamine (**1**) (5.37 mL, 50.0 mmol) in THF (100 mL) was added a solution of Boc<sub>2</sub>O (3.27 g, 15.0 mmol) in THF (30 mL) dropwise at 0 °C. The reaction mixture was stirred at room temperature for 5 h and then concentrated in vacuo. The obtained residue was subsequently diluted with EtOAc and satd NaHCO<sub>3</sub> aq. The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude carbamate (2.82 g, 15.0 mmol, quant, pale yellow powder) was used for the next step without further purification.

The obtained carbamate (2.82 g) in THF (30 mL) was treated with Et<sub>3</sub>N (1.62 mL, 11.6 mmol) followed by 2-nitrobenzyl 4-nitrophenyl carbonate (**2**)<sup>15</sup> (3.69 g, 11.6 mmol). The reaction mixture was stirred at room temperature for 4 h and then concentrated in vacuo and diluted with EtOAc and 5% KHSO<sub>4</sub> aq. The obtained mixture was extracted three times with EtOAc. The combined organic layer was washed with satd NaHCO<sub>3</sub> aq and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The crude material was purified by column chromatography (*n*-hexane/EtOAc = 8/1 then 1/1) to afford *o*-NBnoc-diamine **3** (4.26 g, 11.6 mmol, quant) as a yellow oil: IR (CHCl<sub>3</sub>)  $\nu_{\text{max}}$  cm<sup>-1</sup> 1364, 1477, 1529, 1701, 2875, 2977, 3358; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 100 °C, 300 MHz)  $\delta$  = 1.09 (3H, t, *J* = 7.0 Hz), 1.38 (9H, s), 3.11 (2H, dt, *J* = 6.6 and 6.6 Hz), 3.22–3.35 (4H, m), 5.39 (2H, s), 6.35–6.47 (1H, br m), 7.60 (1H, dd, *J* = 8.1 and 7.5 Hz), 7.67 (1H, d, *J* = 7.3 Hz), 7.76 (1H, dd, *J* = 7.3 and 7.5 Hz), 8.05 (1H, d, *J* = 8.1 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 60 °C, 75 MHz)  $\delta$  = 13.1, 28.0, 41.9, 62.7, 77.5, 124.3, 128.7, 128.8, 132.1, 133.6, 147.2, 154.5, 155.3; HRMS (ESI-TOF) *m/z* calcd for C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>NaO<sub>6</sub> ([*M* + Na]<sup>+</sup>) 390.1641, found 390.1643.

*2-Nitrobenzyl (2-Aminoethyl) Ethylcarbamate (4a)*. Carbamate **3** (2.00 g, 2.72 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.36 mL) was treated with trifluoroacetic acid (1.36 mL). The reaction mixture was stirred at room temperature for 45 min and concentrated in vacuo. After dilution of the resulting residue with EtOAc and satd NaHCO<sub>3</sub> aq, the solution was extracted three times with EtOAc. The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. Crude *o*-NBoc amine **4a** (1.45 g) was obtained as yellow powder. The obtained crude **4a** was used for preparation of **9a** and **14a** without further purification.

*tert-Butyl (2-Aminoethyl) Ethylcarbamate (4b)*. To a stirred mixture of *N*-ethylethylenediamine (**1**) (2.39 mL, 22.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added ethyl trifluoroacetate (3.46 mL, 22.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) dropwise over 40 min at 0 °C. The reaction mixture was stirred at room temperature for 1 h and then concentrated in vacuo. After dilution of the resulting residue with CH<sub>2</sub>Cl<sub>2</sub> (100 mL), to the solution was added Boc<sub>2</sub>O (4.95 g, 22.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1.5 h and then diluted with EtOAc and satd NaHCO<sub>3</sub> aq. The solution was extracted three times with EtOAc. The combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude material in MeOH (90 mL) and H<sub>2</sub>O (10 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (2.00 g). The reaction mixture was refluxed for 2 h and then concentrated in vacuo. The mixture was extracted three times with EtOAc. The combined organic layer was washed with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub>, filtrated, and concentrated in vacuo. Crude Boc amine **4b** (4.27 g) was obtained as pale yellow oil. The obtained crude **4b** was used for preparation of **9b** and **14b** without further purification.

*(S)-3-[[Allyloxy]carbonyl]amino]-2,2-dimethylsuccinic Acid 4-Allyl Ester (8)* and *(S)-4-(Allyloxy)-2-[[allyloxy]carbonyl]amino]-3,3-dimethyl-4-oxobutanoic Acid (17)*. To a solution of PhFI-diMe-Asp(OMe)-OMe (**5**)<sup>16</sup> (1.83 g, 4.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10.2 mL) was added triethylsilane (1.43 mL, 14.2 mmol) followed by trifluoroacetic acid (10.2 mL) at 0 °C. The reaction mixture was stirred at room

temperature for 1 h and concentrated in vacuo. The obtained mixture was diluted with 1 M HCl aq. The precipitate was filtrated and washed with MeOH. The filtrate was concentrated in vacuo, and the resulting crude amine was used for a next step without further purification.

The crude amine in THF (12.5 mL) and H<sub>2</sub>O (8.96 mL) was treated with NaHCO<sub>3</sub> (2.51 g, 29.9 mmol) followed by allyl chloroformate (63.6 μL, 5.98 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 9 h and diluted with H<sub>2</sub>O and EtOAc. The mixture was extracted three times with EtOAc. The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude Alloc-diMe-Asp(OMe)-OMe (**7**) was used for next step without further purification.

The crude **7** in THF (10.9 mL) and H<sub>2</sub>O (30 mL) was treated with 1 M LiOH aq (17.4 mL, 17.4 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 10 h and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The aqueous layer was washed three times with CH<sub>2</sub>Cl<sub>2</sub> and then acidified (pH ≈ 3) with 3 M HCl aq. To the aqueous layer were added EtOAc and NaCl. The mixture was extracted three times with EtOAc. The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. Crude carboxylic acid (1.22 g) was obtained as a colorless oil. A 600 mg portion was used for the next step without further purification.

The stirred mixture of obtained crude carboxylic acid (600 mg) in THF (2.43 mL) was treated with Ac<sub>2</sub>O (616 μL, 6.56 mmol). The reaction mixture was refluxed for 18 h and then concentrated in vacuo. To the obtained crude anhydride was added allyl alcohol (7.5 mL). The reaction mixture was stirred at room temperature for 23 h and concentrated in vacuo. The obtained crude material was purified by column chromatography (chloroform/MeOH = 400/1 then 50/1) to afford **8** (449 mg, 1.47 mmol, 61% over five steps from **5**) as a colorless oil and **17** (131 mg, 0.459 mmol, 19% over five steps from **5**) as colorless oil. **8**: [α]<sub>D</sub><sup>28</sup> -12.3 (c 1.56, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) ν<sub>max</sub> cm<sup>-1</sup> 1330, 1519, 1713, 2886, 2942, 3084, 3349; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ = 1.26 (3H, s), 1.37 (3H, s), 4.58–4.67 (5H, m), 5.21–5.27 (2H, m), 5.29–5.36 (2H, m), 5.66 (br d, J = 9.6 Hz), 5.85–5.98 (2H, m); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ = 22.2, 23.3, 45.7, 59.8, 66.0, 66.4, 118.2, 118.7, 131.9, 132.5, 156.5, 175.1, 175.3; HRMS (ESI-TOF) *m/z* calcd for C<sub>13</sub>H<sub>19</sub>N<sub>1</sub>NaO<sub>6</sub> ([M + Na]<sup>+</sup>) 308.1110, found 308.1115. **17**: [α]<sub>D</sub><sup>28</sup> -11.8 (c 2.40, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) ν<sub>max</sub> cm<sup>-1</sup> 932, 1251, 1525, 1724, 2886, 2944, 2984, 3088, 3350; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ = 1.23 (3H, s), 1.34 (3H, s), 4.57–4.67 (5H, m), 5.20–5.26 (2H, m), 5.28–5.36 (2H, m), 5.68 (1H, br d, J = 10.4), 5.81–5.98 (2H, m); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ = 22.1, 23.3, 45.6, 59.9, 66.3, 66.4, 118.2, 119.3, 131.3, 132.6, 156.4, 170.2, 181.5; HRMS (ESI-TOF) *m/z* calcd for C<sub>25</sub>H<sub>19</sub>N<sub>1</sub>NaO<sub>6</sub> ([M + Na]<sup>+</sup>) 308.1110, found 308.1121.

Allyl (*S*)-2-[[Allyloxy]carbonyl]amino]-4-[[2-ethyl(2-nitrobenzyloxycarbonyl)aminoethyl]amino]-3,3-dimethyl-4-oxobutanoate (**9a**). To a solution of **8** (34.5 mg, 0.121 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (605 μL) were added crude **4a** (93.8 mg), bromotripyrrolidinophosphonium hexafluorophosphate (PyBrop) (152 mg, 0.454 mmol) and N<sub>1</sub>N-diisopropylethylamine (DIPEA) (77.2 μL, 0.454 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 34 h and then diluted with EtOAc and 5% KHSO<sub>4</sub> aq. The solution was extracted three times with EtOAc. The combined organic layer was washed with satd NaHCO<sub>3</sub> aq, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude material was purified with column chromatography (*n*-hexane/EtOAc = 1/1 then 1/2) to afford amide **9a** (48.0 mg, 90.4 μmol, 75%) as a colorless oil: [α]<sub>D</sub><sup>28</sup> -2.9 (c 1.25, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) ν<sub>max</sub> cm<sup>-1</sup> 1268, 1342, 1427, 1526, 1650, 1703, 2875, 2939, 2973, 3079, 3361; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 70 °C, 300 MHz) δ = 1.08 (3H, t, J = 7.1 Hz), 1.13 (3H, s), 1.14 (3H, s), 3.19–3.35 (6H, m), 4.46–4.59 (5H, m), 5.13–5.24 (2H, m), 5.24–5.36 (2H, m), 5.4 (2H, s), 5.81–5.98 (2H, m), 7.16 (1H, br d, J = 2.9 Hz), 7.46–7.55 (1H, br m), 7.60 (1H, dd, J = 7.1, 8.0 Hz), 7.69 (1H, br d, J = 7.2 Hz), 7.78 (1H, dd, J = 7.1, 7.2 Hz), 8.07 (1H, d, J = 8.0 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 70 °C, 75 MHz) δ = 13.0, 21.1, 22.6, 37.7, 41.8, 44.1, 45.3, 59.7, 62.7, 64.4, 64.5, 116.6, 117.4, 124.2, 128.7, 128.9, 131.9, 132.0, 133.1, 147.3, 154.5, 155.7, 169.7, 174.6; HRMS

(ESI-TOF) *m/z* calcd for C<sub>25</sub>H<sub>34</sub>N<sub>4</sub>NaO<sub>9</sub> ([M + Na]<sup>+</sup>) 557.2223, found 557.2244.

(*S*)-2-[[[9H-Fluoren-9-yl)methoxycarbonyl]amino]-4-[[2-ethyl(2-nitrobenzyloxycarbonyl)amino ethyl]amino]-3,3-dimethyl-4-oxobutanoic Acid (**10a**). To a stirred mixture of **9a** (20.2 mg, 37.4 μmol) in THF were added Pd(PPh<sub>3</sub>)<sub>4</sub> (6.49 mg, 5.61 μmol) and *N*-methylaniline (40.8 μL, 0.374 mmol). The reaction mixture was stirred at room temperature for 6 h. To the reaction mixture were added DIPEA (15.3 μL, 89.8 μmol) and FmocOSu (15.1 mg, 44.9 μmol) at 0 °C. The reaction mixture was stirred at room temperature for 10 h and diluted with EtOAc and 5% KHSO<sub>4</sub> aq. The solution was extracted three times with EtOAc. The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude material was purified with column chromatography (CHCl<sub>3</sub>/MeOH = 150/1 then 30/1) to afford carboxylic acid **10a** (21.7 mg, 34.3 μmol, 92%) as pale yellow oil: [α]<sub>D</sub><sup>28</sup> -1.1 (c 1.30, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) ν<sub>max</sub> cm<sup>-1</sup> 930, 1249, 1367, 1530, 1672, 1726, 2875, 2934, 2975, 3079, 3350; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 50 °C, 300 MHz) δ = 1.03–1.20 (6H, m), 1.25 (3H, s), 3.30 (2H, q, J = 7.1 Hz), 3.34–3.57 (4H, m), 4.18 (1H, t, J = 6.8 Hz), 4.37 (2H, d, J = 6.8 Hz), 4.42–4.58 (1H, m), 5.47 (2H, s), 6.03–6.13 (1H, m), 6.79–6.94 (1H, m), 7.24–7.61 (9H, m), 7.71 (2H, d, J = 7.5 Hz), 7.98 (1H, d, J = 7.9 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ = 13.9, 23.2, 23.6, 40.7, 43.0, 45.5, 45.9, 47.3, 60.0, 64.7, 67.5, 120.1, 125.2, 125.3, 127.2, 127.9, 128.9, 129.1, 129.3, 132.3, 133.8, 141.4, 143.8, 143.9, 147.9, 149.0, 156.9, 157.6, 172.3; HRMS (ESI-TOF) *m/z* calcd for C<sub>33</sub>H<sub>37</sub>N<sub>4</sub>O<sub>9</sub> ([M + H]<sup>+</sup>) 633.2561, found 633.2549.

Allyl (*S*)-2-[[Allyloxy]carbonyl]amino]-4-[[2-(tert-butoxycarbonyl)ethyl]aminoethyl]amino]-3,3-dimethyl-4-oxobutanoate (**9b**). Amide **9b** was prepared from carboxylic acid **8** (72.0 mg, 0.252 mmol) and crude **4b** (96 mg) in a manner similar to that described for preparation of **9a**. compound **9b** (109 mg, 0.239 mmol, 95%) was obtained as a colorless oil: [α]<sub>D</sub><sup>28</sup> -6.7 (c 2.18, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) ν<sub>max</sub> cm<sup>-1</sup> 1341, 1431, 1525, 1709, 2880, 2934, 2975, 3317; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ = 1.10 (3H, t, J = 7.0 Hz), 1.25 (3H, s), 1.35 (3H, s), 1.46 (3H, s), 3.21 (2H, q, J = 7.0 Hz), 3.28–3.50 (4H, br m), 4.32 (2H, d, J = 9.2 Hz), 4.57 (2H, ddd, J = 1.6, 1.6, 5.6 Hz), 4.60 (2H, ddd, J = 1.6, 1.6, 5.6 Hz), 5.16–5.25 (2H, m), 5.26–5.35 (2H, m), 5.82–5.97 (2H, m), 6.38 (2H, br d, J = 9.2 Hz), 7.05–7.20 (1H, br m); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ = 13.9, 23.5, 24.6, 28.6, 41.1, 43.0, 44.5, 45.5, 61.3, 65.9, 80.3, 117.6, 118.6, 131.8, 132.9, 156.5, 157.6, 170.6, 176.3; HRMS (ESI-TOF) *m/z* calcd for C<sub>22</sub>H<sub>37</sub>N<sub>3</sub>NaO<sub>7</sub> ([M + Na]<sup>+</sup>) 478.2529, found 478.2539.

(*S*)-2-[[[9H-Fluoren-9-yl)methoxycarbonyl]amino]-4-[[2-(tert-butoxycarbonyl)ethyl]aminoethyl]amino]-3,3-dimethyl-4-oxobutanoic Acid (**10b**). Carboxylic acid **10b** was prepared from amide **9b** (88.8 mg, 0.195 mmol) in a manner similar to that described for **10a**. Compound **10b** (72.2 mg, 0.136 mmol, 70%) was obtained as a pale yellow oil: [α]<sub>D</sub><sup>28</sup> -1.0 (c 2.16, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) ν<sub>max</sub> cm<sup>-1</sup> 1366, 1450, 1479, 1531, 1709, 2875, 2934, 2975, 3329; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ = 1.11 (3H, t, J = 7.2 Hz), 1.24 (3H, s), 1.36 (3H, s), 1.46 (9H, s), 3.22 (2H, q, J = 7.2 Hz), 3.3–3.47 (4H, m), 4.22 (1H, t, J = 7.2 Hz), 4.30 (2H, d, J = 7.2 Hz), 4.56 (1H, br d, J = 8.0 Hz), 6.11–6.26 (1H, br m), 7.31 (2H, dd, J = 7.6, 7.6 Hz), 7.39 (2H, dd, J = 9.2, 7.6 Hz), 7.57–7.65 (2H, m), 7.75 (2H, d, J = 9.2 Hz), 7.77–7.85 (1H, br m); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ = 13.8, 23.4, 23.7, 28.5, 41.5, 43.2, 45.3, 45.5, 47.3, 60.1, 67.4, 80.8, 120.1, 125.3, 127.2, 127.8, 141.4, 143.8, 144.0, 156.8, 157.8, 172.1, 178.9; HRMS (ESI-TOF) *m/z* calcd for C<sub>30</sub>H<sub>39</sub>N<sub>3</sub>NaO<sub>7</sub> ([M + Na]<sup>+</sup>) 576.2686, found 576.2672.

2-Nitrobenzyl 2-[[2,4-Dimethoxybenzyl]amino]ethyl Ethylcarbamate (**14a**). Crude amine **4a** (1.24 g) in MeOH (8.9 mL) was treated with 2,4-dimethoxybenzaldehyde (1.23 g, 7.41 mmol), AcOH (278 μL, 4.86 mmol), and Na<sub>2</sub>SO<sub>4</sub> (3.29 g, 46.3 mmol). The reaction mixture was stirred at room temperature for 2 h. To the reaction mixture was added NaBH<sub>4</sub> (700 mg, 18.5 mmol) at 0 °C. The reaction mixture was additionally stirred at room temperature for 1 h and then diluted with satd NaHCO<sub>3</sub> aq. The mixture was extracted three times with EtOAc. The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude material was purified with column chromatography (*n*-hexane/EtOAc = 2/1 then




EtOAc/MeOH 3/1) to afford DMB-*o*-NBoc amine **14a** (1.84 g, 4.41 mmol, 95% over two steps) as a light brown oil: IR (CHCl<sub>3</sub>)  $\nu_{\text{max}}$  cm<sup>-1</sup> 1343, 1423, 1465, 1529, 1613, 1701, 2836, 2935, 3340; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 80 °C, 300 MHz)  $\delta$  = 1.09 (3H, t, *J* = 7.0 Hz), 1.38 (9H, s), 3.11 (2H, dt, *J* = 6.6, 6.6 Hz), 3.21–3.37 (4H, m), 5.39 (2H, s), 6.33–6.48 (1H, br m), 7.60 (1H, dd, *J* = 8.1, 7.6 Hz), 7.68 (1H, d, *J* = 7.3 Hz), 7.76 (1H, dd, *J* = 7.3, 7.5 Hz), 8.05 (1H, d, *J* = 8.1 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 60 °C, 75 MHz)  $\delta$  = 13.1, 28.0, 38.5, 41.9, 46.1, 62.7, 77.5, 124.3, 128.7, 128.8, 132.1, 133.6, 147.2, 154.5, 155.3; HRMS (ESI-TOF) *m/z* calcd for C<sub>21</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub> ([M + Na]<sup>+</sup>) 418.1978, found 418.1988.

*tert*-Butyl 2-[(2,4-Dimethoxybenzyl)amino]ethyl Ethylcarbamate (**14b**). DMB-Boc-amine **14b** was prepared from amine crude **4b** (500 mg) and 2,4-dimethoxybenzaldehyde (221 mg, 1.33 mmol) in a manner similar to that described for **14a**. Compound **14b** (396 mg, 1.17 mmol, 88%) was obtained as a yellow oil: IR (CHCl<sub>3</sub>)  $\nu_{\text{max}}$  cm<sup>-1</sup> 1156, 1366, 1463, 1507, 1613, 1690, 2837, 2933, 2973, 3342; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 60 °C, 300 MHz)  $\delta$  = 1.02 (3H, t, *J* = 7.0 Hz), 1.38 (9H, s), 2.69 (2H, t, *J* = 6.8 Hz), 3.17 (2H, q, *J* = 7.0 Hz), 3.25 (2H, t, *J* = 6.8 Hz), 3.70 (2H, s), 3.76 (3H, s), 3.78 (3H, s), 6.59 (1H, br s), 6.48 (1H, dd, *J* = 8.3, 2.2 Hz), 6.55 (1H, d, *J* = 2.2 Hz), 7.18 (1H, d, *J* = 8.3 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  = 13.6, 28.5, 42.5, 46.6, 47.3, 48.7, 55.4, 55.5, 70.6, 77.2, 79.4, 98.6, 103.8, 120.2, 130.6, 158.7, 160.3; HRMS (ESI-TOF) *m/z* calcd for C<sub>18</sub>H<sub>31</sub>N<sub>2</sub>O<sub>4</sub> ([M + H]<sup>+</sup>) 339.2284, found 339.2281.

Allyl (S)-2-[(Allyloxycarbonyl)amino]-4-[[2,4-dimethoxybenzyl](2-ethyl-2-nitrobenzoyloxycarbonyl aminoethyl)amino]-3,3-dimethyl-4-oxobutanoate (**15**). To a solution of carboxylic acid **8** (118 mg, 0.413 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added Et<sub>3</sub>N (173  $\mu$ L, 1.24 mmol) followed by the addition of MsCl (38.4  $\mu$ L, 0.496 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100  $\mu$ L) at 0 °C. The reaction mixture was stirred at the same temperature for 2 h. After addition of **14a** (199 mg, 0.476 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) to the reaction mixture at 0 °C, The resulting mixture was stirred at room temperature for an additional 17 h and then diluted with EtOAc and 5% KHSO<sub>4</sub> aq. The solution was extracted three times with EtOAc. The combined organic layer was washed with satd NaHCO<sub>3</sub> aq and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude material was purified with column chromatography (*n*-hexane/EtOAc = 13/7 then 3/2) to afford amide **15** (140 mg, 0.204 mmol, 50%) as a colorless oil: [ $\alpha$ ]<sub>D</sub><sup>29</sup> -0.4 (c 0.80, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>)  $\nu_{\text{max}}$  cm<sup>-1</sup> 1208, 1423, 1477, 1528, 1614, 1707, 2838, 2939, 2972, 3084, 3314, 3443; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 100 °C, 300 MHz)  $\delta$  = 1.04 (3H, t, *J* = 7.0 Hz), 1.27 (3H, s), 1.33 (3H, s), 3.21 (3H, q, *J* = 7.0 Hz), 3.26–3.44 (4H, m), 3.76 (3H, s), 3.78 (3H, s), 4.50–4.64 (7H, m), 5.12–5.24 (2H, m), 5.26–5.38 (4H, m), 5.77–6.11 (2H, m), 6.49 (1H, dd, *J* = 8.4, 2.0 Hz), 6.56 (1H, d, *J* = 2.0 Hz), 6.85 (1H, br d, *J* = 9.3 Hz), 6.99 (1H, d, *J* = 8.4 Hz), 7.54–7.63 (2H, m), 7.71 (1H, t, *J* = 7.5 Hz), 8.03 (1H, d, *J* = 8.1 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz, rotamer)<sup>20</sup>  $\delta$  = 13.2, 13.9, 24.2, 25.3, 25.5, 29.6, 42.4, 43.1, 43.6, 43.7, 44.1, 44.3, 45.5, 46.4, 47.6, 55.1, 55.3, 63.2, 63.5, 63.7, 65.7, 98.4, 104.0, 116.6, 117.0, 117.4, 117.5, 117.9, 118.1, 124.8, 128.2, 128.3, 128.4, 128.5, 128.7, 131.8, 131.9, 132.7, 133.1, 133.2, 133.5, 133.6, 155.0, 155.4, 156.8, 157.9, 160.2, 160.3, 170.7, 176.2, 176.3, 176.4; HRMS (ESI-TOF) *m/z* calcd for C<sub>34</sub>H<sub>44</sub>N<sub>4</sub>NaO<sub>11</sub> ([M + Na]<sup>+</sup>) 707.2904, found 707.2924.

#### Synthesis of $\alpha$ -Amide-Protected Derivatives **16** and **27**.



Allyl (S)-3-[(Allyloxycarbonyl)amino]-4-[[2,4-dimethoxybenzyl][2-ethyl-2-nitrobenzoyloxycarbonyl aminoethyl]amino]-2,2-dimethyl-4-oxobutanoate (**25**). Carboxylic acid **17** (90.6 mg, 0.318 mmol) in THF (3.1 mL) was treated with Et<sub>3</sub>N (133  $\mu$ L, 0.953 mmol). Following addition of MsCl (29.5  $\mu$ L, 0.381 mmol) at 0 °C, the reaction mixture was stirred at the same temperature for 30 min. After addition of **14a** (199 mg, 0.476 mmol) to the reaction mixture at 0 °C, the resulting solution was stirred at room temperature for an additional 20 h and then diluted with EtOAc and 5% KHSO<sub>4</sub> aq. The solution was extracted three times with EtOAc. The combined organic layer was washed with satd NaHCO<sub>3</sub> aq and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude material was purified with column chromatography (*n*-hexane/EtOAc = 2/1 then 1/1) to afford amide **25** (130 mg, 0.190 mmol, 60%) as a colorless oil: [ $\alpha$ ]<sub>D</sub><sup>28</sup> -16.8 (c 1.03, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>)  $\nu_{\text{max}}$  cm<sup>-1</sup>: 1209, 1343, 1426, 1509, 1529, 1645, 1709, 2939, 2976, 3196; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 100 °C, 300 MHz)  $\delta$  = 1.04 (3H, br t, *J* = 6.1 Hz), 1.15 (3H, s), 1.24 (3H, s), 3.13–3.62 (6H, br m), 3.76 (6H, s), 4.33–4.64 (6H, m), 4.74–4.97 (1H, br m), 5.08–5.23 (2H, m), 5.23–5.34 (2H, m), 5.37 (2H, s), 5.78–6.02 (2H, m), 6.45 (1H, d, *J* = 8.2 Hz), 6.55 (1H, s), 6.85 (1H, br d, *J* = 9.0 Hz), 7.03 (1H, d, *J* = 8.2 Hz), 7.52–7.67 (2H, m), 7.73 (1H, dd, *J* = 7.4, 7.4 Hz), 8.04 (1H, dd, *J* = 8.1 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 100 °C, 75 MHz)  $\delta$  = 12.7, 21.0, 22.5, 41.6, 43.3, 43.4, 44.9, 45.5, 54.8, 55.1, 55.8, 62.4, 64.1, 64.4, 98.4, 104.7, 116.5, 116.8, 123.9, 128.4, 128.7, 131.6, 132.2, 132.8, 133.1, 147.3, 154.2, 155.1, 157.9, 159.8, 169.3, 174.6; HRMS (ESI-TOF) *m/z* calcd for C<sub>34</sub>H<sub>44</sub>N<sub>4</sub>NaO<sub>11</sub> ([M + Na]<sup>+</sup>) 707.2904, found 707.2933.


(S)-3-[[9H-Fluoren-9-yl]methoxycarbonyl]amino]-4-[[2,4-dimethoxybenzyl][2-ethyl(2-nitrobenzoyloxycarbonyl)aminoethyl]amino]-2,2-dimethyl-4-oxobutanoic Acid (**16**). Carboxylic acid **16** was prepared from amide **25** (55.5 mg, 81.1  $\mu$ mol) in a manner similar to that described for **10a**. Compound **16** (63.0 mg, 80.5  $\mu$ mol, quant) was obtained as pale yellow amorphous: [ $\alpha$ ]<sub>D</sub><sup>28</sup> -8.2 (c 1.49, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>)  $\nu_{\text{max}}$  cm<sup>-1</sup> 1342, 1452, 1508, 1526, 1613, 1645, 1708, 2853, 2931, 2961, 3068, 3421; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 100 °C, 300 MHz)  $\delta$  = 0.97 (3H, t, *J* = 7.0 Hz), 1.04 (3H, s), 1.14 (3H, s), 3.12–3.43 (6H, br m), 3.66 (3H, s), 3.68 (3H, s), 4.01–4.57 (5H, br m), 4.75 (1H, br d, *J* = 1.8 Hz), 5.31 (2H, s), 6.34 (1H, dd, *J* = 8.3, 2.0 Hz), 6.47 (1H, d, *J* = 2.0 Hz), 6.84–7.07 (2H, m), 7.16–7.29 (2H, m), 7.34 (2H, dd, *J* = 7.5, 7.1 Hz), 7.46–7.72 (5H, m), 7.79 (2H, d, *J* = 7.5 Hz), 7.97 (1H, 7.9 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 75 MHz, rotamer)<sup>20</sup>  $\delta$  = 13.1, 13.7, 20.8, 21.0, 24.3, 42.2, 42.3, 43.1, 44.9, 45.8, 45.9, 46.7, 55.0, 55.4, 55.6, 55.9, 63.2, 65.9, 98.1, 98.3, 104.3, 104.5, 116.4, 117.0, 120.2, 124.7, 125.4, 127.0, 127.7, 128.7, 129.0, 132.3, 132.6, 134.1, 134.2, 140.7, 143.5, 143.7, 143.8, 154.3, 154.7, 156.0, 156.3, 158.0, 158.2, 159.7, 160.2, 169.9, 177.5, 177.7; HRMS (ESI-TOF) *m/z* calcd for C<sub>42</sub>H<sub>46</sub>N<sub>4</sub>NaO<sub>11</sub> ([M + Na]<sup>+</sup>) 805.3061, found 805.3063.

Allyl (S)-3-[(Allyloxycarbonyl)amino]-4-[[2-ethyl(tert-butoxycarbonyl)aminoethyl][2,4-dimethoxybenzyl]amino]-2,2-dimethyl-4-oxobutanoate (**26**). Amide **26** was prepared from **17** (63.5 mg, 0.223 mmol) and **14b** (113 mg) in a manner similar to that described for **25**. Compound **26** (74.6 mg, 0.122 mmol, 55%) was obtained as a colorless oil: [ $\alpha$ ]<sub>D</sub><sup>28</sup> -1.8 (c 1.07, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>)  $\nu_{\text{max}}$  cm<sup>-1</sup> 1366, 1507, 1646, 1693, 1723, 2832, 2875, 2934, 2975; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 100 °C, 300 MHz)  $\delta$  = 0.88–1.11 (3H, m), 1.16 (3H, s), 1.13 (3H, s), 1.38 (9H), 3.03–3.60 (6H, br m), 3.77 (3H, s), 3.79 (3H, s), 4.38–4.65 (6H, m), 4.84 (1H, br d, *J* = 9.0 Hz), 5.11–5.24 (2H, m), 5.24–5.41 (2H, m), 5.75–6.06 (2H, m), 6.48 (1H, br d, *J* = 7.7 Hz), 6.57 (1H, s), 6.83 (1H, br d, *J* = 9.0 Hz), 7.03 (1H, br d, *J* = 7.7 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 100 °C, 75 MHz)  $\delta$  = 12.8, 21.1, 22.6, 27.6, 41.3, 43.5, 44.8, 45.5, 54.8, 55.0, 55.8, 64.1, 64.4, 78.1, 98.3, 104.7, 116.4, 116.7, 128.7, 132.2, 132.8, 153.9, 155.0, 157.8, 159.8, 169.2, 174.6; HRMS (ESI-TOF) *m/z* calcd for C<sub>31</sub>H<sub>47</sub>N<sub>3</sub>NaO<sub>9</sub> ([M + Na]<sup>+</sup>) 628.3210, found 628.3234.

(S)-3-[[9H-Fluoren-9-yl]methoxycarbonyl]amino]-4-[[2-ethyl(tert-butoxycarbonyl)aminoethyl][2,4-dimethoxybenzyl]amino]-2,2-dimethyl-4-oxobutanoic Acid (**27**). Carboxylic acid **27** was prepared from amide **26** (55.9 mg, 92.3  $\mu$ mol) in a manner similar to that described for **10a**. Compound **27** (64.7 mg, 92.0  $\mu$ mol, quant) was obtained as a pale yellow amorphous solid: [ $\alpha$ ]<sub>D</sub><sup>25</sup> -1.5 (c 0.80, CHCl<sub>3</sub>);

IR (CHCl<sub>3</sub>)  $\nu_{\max}$  cm<sup>-1</sup> 1160, 1210, 1455, 1508, 1616, 1643, 1692, 1718, 2928, 2973, 3277; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 100 °C, 300 MHz)  $\delta$  = 0.10 (3H, t, *J* = 7.1 Hz), 1.12 (3H, s), 1.22 (1H, s), 1.38 (9H, s), 3.10–3.44 (6H, br m), 3.72 (3H, s), 3.77 (3H, s), 4.07–4.25 (1H, br m), 4.25–4.41 (2H, br m), 4.41–4.61 (2H, br m), 4.81 (1H, br d, *J* = 6.2 Hz), 6.42 (1H, dd, *J* = 8.3, 2.0 Hz), 6.55 (1H, d, *J* = 2.0 Hz), 7.25–7.36 (2H, m), 7.40 (2H, dd, *J* = 7.3, 7.5 Hz), 7.67 (2H, d, *J* = 7.0 Hz), 7.84 (2H, d, *J* = 7.3 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 75 MHz, rotamer)<sup>20</sup>  $\delta$  = 13.5, 20.8, 20.9, 24.1, 24.3, 28.0, 42.8, 43.6, 44.8, 45.8, 46.6, 46.7, 55.0, 55.2, 55.3, 55.7, 65.9, 66.0, 78.5, 78.7, 98.2, 98.3, 104.3, 104.4, 116.4, 116.9, 120.1, 125.3, 125.4, 127.0, 127.3, 127.7, 128.9, 140.7, 143.5, 143.6, 143.8, 156.0, 156.3, 157.8, 158.0, 159.6, 159.9, 169.9, 177.6, 177.7; HRMS (ESI-TOF) *m/z* calcd for C<sub>39</sub>H<sub>49</sub>N<sub>3</sub>NaO<sub>9</sub> ([M + Na]<sup>+</sup>) 726.3367, found 726.3365.

#### Synthesis of 29 for Preparation of Peptide 19.



**Allyl N<sup>2</sup>-[[[(9H-Fluoren-9-yl)methoxy]carbonyl]-N<sup>4</sup>-[2-[(tert-butoxycarbonyl)ethylamino]ethyl]-N<sup>4</sup>-(2,4-dimethoxybenzyl)-L-asparagine (28).** To a stirred mixture of Fmoc-L-Asp(OH)-OAllyl<sup>19</sup> (350 mg, 0.886 mmol) and 14b (250 mg, 0.739 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added EDC·HCl (170 mg, 0.886 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h and diluted with EtOAc and 5% KHSO<sub>4</sub> aq. The solution was extracted three times with EtOAc. The combined organic layer was washed with brine, satd NaHCO<sub>3</sub> aq, and brine, dried over MgSO<sub>4</sub>, filtrated, and concentrated in vacuo. The obtained crude material was purified with column chromatography (*n*-hexane/EtOAc = 1/1) to afford amide 28 (500 mg, 0.698 mmol, 95%) as a pale yellow oil: [ $\alpha$ ]<sub>D</sub><sup>25</sup> 22.8 (*c* 2.13, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>)  $\nu_{\max}$  cm<sup>-1</sup> 1289, 1454, 1506, 1642, 1690, 1725, 2838, 2934, 2972, 3438; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 100 °C, rotamer, 300 MHz)  $\delta$  = 1.01 (3H, t, *J* = 7.0 Hz), 1.39 (9H, s), 2.89–2.95 (2H, m), 3.09–3.23 (4H, m), 3.33 (2H, br t, *J* = 6.3 Hz), 3.75 (3H, s), 3.79 (3H, s), 4.20–4.28 (1H, m), 4.30–4.36 (2H, m), 4.38–4.51 (2H, m), 4.56–4.63 (3H, m), 5.18 (1H, dd, *J* = 10.4, 1.5 Hz), 5.31 (1H, dd, *J* = 17.2, 1.5 Hz), 5.89 (1H, ddt, *J* = 17.2, 10.4, 5.3 Hz), 6.47 (1H, br d, *J* = 8.2 Hz), 6.58 (1H, s), 7.02 (1H, d, *J* = 8.2 Hz), 7.05–7.21 (1H, m), 7.31 (2H, dd, *J* = 7.5, 7.1 Hz), 7.41 (2H, dd, *J* = 7.5, 7.1 Hz), 7.67 (2H, d, *J* = 7.3 Hz), 7.85 (2H, d, *J* = 7.5 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 75 MHz, rotamer)<sup>20</sup>  $\delta$  = 13.3, 13.8, 28.0, 34.0, 34.7, 41.5, 42.1, 42.7, 43.6, 44.7, 44.9, 46.3, 46.6, 50.5, 50.9, 55.1, 55.2, 55.3, 55.4, 64.9, 65.0, 65.8, 78.4, 78.9, 98.2, 98.5, 104.3, 104.5, 116.3, 117.4, 117.6, 120.1, 125.2, 127.1, 127.6, 128.2, 128.4, 128.9, 132.3, 132.4, 140.7, 143.7, 155.7, 155.8, 157.9, 159.7, 160.2, 169.1, 169.6, 171.1, 171.3; HRMS (ESI-TOF) *m/z* calcd for C<sub>40</sub>H<sub>49</sub>N<sub>3</sub>NaO<sub>9</sub> ([M + Na]<sup>+</sup>) 738.3367, found 738.3389.

**N<sup>2</sup>-[[[(9H-Fluoren-9-yl)methoxy]carbonyl]-N<sup>4</sup>-[2-[(tert-butoxycarbonyl)ethylamino]ethyl]-N<sup>4</sup>-(2,4-dimethoxybenzyl)-L-asparagine (29).** To a solution of amide 28 (450 mg, 0.629 mmol) in THF (6.0 mL) were added Pd(PPh<sub>3</sub>)<sub>4</sub> (72.7 mg, 62.9  $\mu$ mol) and *N*-methylaniline (685  $\mu$ L, 6.29 mmol). The reaction mixture was stirred at room temperature for 1 h and concentrated in vacuo. The obtained crude material was purified with column chromatography (*n*-hexane/EtOAc = 1/1 then EtOAc/MeOH = 10/1) to afford carboxylic acid 29 (394 mg, 0.583 mmol, 93%) as a pale yellow amorphous solid: [ $\alpha$ ]<sub>D</sub><sup>25</sup> 39.5 (*c* 1.26, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>)  $\nu_{\max}$  cm<sup>-1</sup> 1289, 1506, 1610, 1643, 1690, 1718, 2843, 2972, 3314, 3427; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 120 °C, rotamer, 300 MHz)  $\delta$  = 1.02 (3H, t, *J* = 7.0 Hz), 1.40 (9H, s), 2.86–2.96 (2H, m), 3.15 (2H, q, *J* = 7.0 Hz), 3.19–3.27 (2H, br m), 3.30–3.42 (2H, br m), 3.75 (3H, s), 3.80 (3H, s), 4.20–4.29 (1H, m), 4.29–4.35 (2H, m), 4.42–4.58 (3H, m), 6.47 (1H, dd, *J* = 8.4, 2.2 Hz), 6.58 (1H, d, *J* = 2.2 Hz), 6.86 (1H, br d, *J* = 7.5 Hz),

7.04 (1H, d, *J* = 8.4 Hz), 7.31 (2H, dd, *J* = 7.5, 7.0 Hz), 7.41 (2H, dd, *J* = 7.5, 7.0 Hz), 7.68 (2H, d, *J* = 7.5 Hz), 7.84 (2H, d, *J* = 7.5 Hz); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 75 MHz, rotamer)<sup>20</sup>  $\delta$  = 13.2, 13.8, 28.0, 33.9, 34.6, 41.5, 42.2, 42.8, 43.6, 44.0, 44.4, 44.9, 45.3, 46.4, 46.6, 50.5, 50.8, 55.1, 55.2, 55.3, 65.8, 66.3, 78.4, 78.7, 78.9, 98.1, 98.5, 104.3, 104.5, 116.4, 117.1, 120.1, 125.2, 127.1, 127.6, 128.2, 128.4, 128.7, 140.7, 143.8, 154.1, 154.6, 155.7, 155.8, 157.9, 159.7, 160.1, 169.4, 169.8, 172.9, 173.2; HRMS (ESI-TOF) *m/z* calcd for C<sub>37</sub>H<sub>45</sub>N<sub>3</sub>NaO<sub>9</sub> ([M + Na]<sup>+</sup>) 698.3054, found 698.3051.

**General Procedures for Peptide Synthesis. Fmoc-Based Solid-Phase Peptide Synthesis (Fmoc SPPS).** On NovaSyn TGR resin (0.22 mmol amine/g) were coupled Fmoc protected naturally occurring amino acid derivatives (5.0 equiv, a protective group of a side chain: *t*-Bu for serine and tyrosine) in the presence of *N,N'*-diisopropylcarbodiimide (DIC, 5.0 equiv) and 1-hydroxybenzotriazole hydrate (HOBT·H<sub>2</sub>O, 5.5 equiv) in DMF for 2 h. Coupling of asparagine derivatives 10a, 16, 10b, or 27 (2 equiv) was performed using *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (1.95 equiv) and *N,N*-diisopropylethyamine (4.0 equiv) for 2 h. For Fmoc removal of the peptide resin, 20% (v/v) piperidine in DMF (10 min) was employed.


**TFA Cleavage.** The resulting completed resin was treated with TFA/*m*-cresol/1,2-ethanedithiol/thioanisole/H<sub>2</sub>O (80/5/5/5/5 (v/v)) for 2 h at room temperature otherwise noted. After filtration of the resin, cooled Et<sub>2</sub>O was added to the filtrate, and the resulting precipitate was collected by centrifugation. The obtained precipitate was washed with Et<sub>2</sub>O and was purified by semipreparative HPLC to give peptides.

**Preparation of Model Peptides 11a, 18, 11b, 19, and 20.** Peptides were synthesized according to the section Fmoc-Based Solid-Phase Peptide Synthesis.

**Fmoc SPPS Using 10a.** Peptide 11a (major peak): a white lyophilized powder (2.08 mg, 1.19  $\mu$ mol, 6.2%); retention time = 16.2 min (analytical HPLC conditions: linear gradient of solvent B in solvent A, 38–50% over 30 min); retention time = 24.2 (semipreparative HPLC conditions: linear gradient of solvent B in solvent A, 38–50% over 30 min); LRMS (ESI-TOF) *m/z* calcd for C<sub>86</sub>H<sub>113</sub>N<sub>17</sub>O<sub>21</sub> ([M + 2H]<sup>2+</sup>) 859.9, found 859.7. Peptide 18 (minor peak): a white lyophilized powder (1.30 mg, 0.699  $\mu$ mol, 3.9%); retention time = 17.6 min (analytical HPLC conditions: linear gradient of solvent B in solvent A, 38–50% over 30 min); retention time = 22.9 (semipreparative HPLC conditions: linear gradient of solvent B in solvent A, 38 to 50% over 30 min); LRMS (ESI-TOF) *m/z* calcd for C<sub>86</sub>H<sub>113</sub>N<sub>17</sub>O<sub>21</sub> ([M + 2H]<sup>2+</sup>) 859.9, found 859.8.

**Fmoc SPPS Using 16 Isomer.** Peptide 18: retention time = 16.3 min (Analytical HPLC conditions: linear gradient of solvent B in solvent A, 38–50% over 30 min); LRMS (ESI-TOF) *m/z* calcd for C<sub>86</sub>H<sub>113</sub>N<sub>17</sub>O<sub>21</sub> ([M + 2H]<sup>2+</sup>) 859.9, found 859.8.

**Fmoc SPPS Using 10b.** Peptide 11b (major peak): a white lyophilized powder (0.75 mg, 0.411  $\mu$ mol, 8.2%); retention time = 18.9 min (analytical HPLC conditions: linear gradient of solvent B in solvent A, 25–40% over 30 min); retention time = 21.4 (semipreparative HPLC conditions: linear gradient of solvent B in solvent A, 27–42% over 30 min); LRMS (ESI-TOF) *m/z* calcd for C<sub>78</sub>H<sub>108</sub>N<sub>16</sub>O<sub>17</sub> ([M + 2H]<sup>2+</sup>) 770.4, found 770.2.



Peptide 30 (minor peak): retention time = a white lyophilized powder (0.39 mg, 0.214  $\mu$ mol, 4.3%); 20.3 min (analytical HPLC conditions: linear gradient of solvent B in solvent A, 25–40% over 30 min); retention time = 23.0 (semipreparative HPLC conditions: linear gradient of solvent B in solvent A, 27 to 42% over 30 min); LRMS (ESI-TOF) *m/z* calcd for C<sub>78</sub>H<sub>108</sub>N<sub>16</sub>O<sub>17</sub> ([M + 2H]<sup>2+</sup>) 770.4, found 770.3.

**Fmoc SPPS Using 27.** Peptide 30: retention time = 20.3 min (analytical HPLC conditions: linear gradient of solvent B in solvent A, 25–40% over 30 min); LRMS (ESI-TOF) *m/z* calcd for C<sub>78</sub>H<sub>108</sub>N<sub>16</sub>O<sub>17</sub> ([M + 2H]<sup>2+</sup>) 770.4, found 770.2.

**Fmoc SPPS Using 29.** Peptide **19**: a white lyophilized powder (12.0 mg, 6.70  $\mu\text{mol}$ , 50%); retention time = 20.4 min (analytical HPLC conditions: linear gradient of solvent B in solvent A, 30–40% over 30 min); retention time = 24.3 (semipreparative HPLC conditions: linear gradient of solvent B in solvent A, 27–41% over 30 min); LRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{76}\text{H}_{104}\text{N}_{16}\text{O}_{17}$  ( $[\text{M} + 2\text{H}]^{2+}$ ) 756.4, found 756.3.

**Fmoc SPPS Using Fmoc-Asn(OtBu)-OH.** Peptide **20**: a white lyophilized powder (8.32 mg, 5.26  $\mu\text{mol}$ , 53%); retention time = 23.5 min (analytical HPLC conditions: linear gradient of solvent B in solvent A, 5–60% over 30 min); retention time = 28.0 (semipreparative HPLC conditions: linear gradient of solvent B in solvent A, 28–42% over 30 min); LRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{72}\text{H}_{95}\text{N}_{15}\text{O}_{17}$  ( $[\text{M} + \text{H}]^+$ ) 1440.7, found 1441.0.

**Self-Processing of Peptide 11b, 19 and 20.** *Self-Processing of Peptide 11b.* A solution of model peptide **11b** (45.0  $\mu\text{g}$ , 25.9 nmol) and benzenesulfonic acid sodium salt (internal standard, 20.7 ng, 0.115 nmol) in phosphate buffer (0.2 M, pH 7.4 and 7.9, 550  $\mu\text{L}$ ) containing 6 M guanidine hydrochloride was incubated at 37  $^{\circ}\text{C}$ , and the reaction was monitored by analytical HPLC. Analytical HPLC conditions: a linear gradient of solvent B in solvent A, 1–60% over 30 min.

The remaining substrate was calculated on the basis of peak areas (= A) of HPLC as follow.  $A^{t=0}$  indicates peak areas at the beginning of the reaction ( $t = 0$ ).

$$\text{remaining substrate (\%)} = \frac{A_{\text{substrate}}/A_{\text{internal standard}}}{A_{\text{substrate}}^{t=0}/A_{\text{internal standard}}^{t=0}} \times 100$$

**11b**: retention time = 21.9 min.


**23** or **24**: retention time = 16.4 min; LRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{38}\text{H}_{57}\text{N}_8\text{O}_9$  ( $[\text{M} + \text{H}]^+$ ) 769.4, found 769.3.

**23** or **24**: retention time = 17.4 min; LRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{38}\text{H}_{57}\text{N}_8\text{O}_9$  ( $[\text{M} + \text{H}]^+$ ) 769.4, found 769.3.

**22**: retention time = 20.1 min; LRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{40}\text{H}_{53}\text{N}_8\text{O}_9$  ( $[\text{M} + \text{H}]^+$ ) 789.4, found 789.2.

Benzenesulfonic acid sodium salt (internal standard): retention time = 7.5 min.

*Self-Processing of Peptide 19.*



The procedure for self-processing of **19** was conducted in a manner similar to that described for **11b** (pH = 7.9).

**19**: retention time = 21.9 min.

**31** or **32**: retention time = 15.6 min; LRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{36}\text{H}_{53}\text{N}_8\text{O}_9$  ( $[\text{M} + \text{H}]^+$ ) 741.4, found 741.3.

**31** or **32**: retention time = 16.3 min; LRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{36}\text{H}_{53}\text{N}_8\text{O}_9$  ( $[\text{M} + \text{H}]^+$ ) 741.4, found 741.3.

**Self-Processing of Peptide 20.** Procedure of self-processing of **20** was conducted in a manner similar to that described for **11b** (pH = 7.9). Almost no split peptide was observed within 24 h.

**20**: retention time = 23.5 min.

**Photoresponsible Amide Bond Cleavage of Peptide 11a.**

Photoresponsible peptide **11a** (45.0  $\mu\text{g}$ , 24.2 nmol) and benzenesulfonic acid sodium salt (internal standard, 3.00 ng, 16.7 pmol) in phosphate buffer (0.2 M, pH 7.4, 515  $\mu\text{L}$ ) containing 6 M guanidine hydrochloride was incubated at 37  $^{\circ}\text{C}$  for 24 h, and the reaction mixture was then irradiated by UV (>365 nm) for 1 min. The resulting solution was incubated at 37  $^{\circ}\text{C}$ . The reaction was monitored by analytical HPLC. Analytical HPLC conditions: a linear gradient of solvent B in solvent A, 1–60% over 30 min.

**11a**: retention time = 28.2 min.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02399.

<sup>1</sup>H and <sup>13</sup>NMR spectra for new compounds (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: aotaka@tokushima-u.ac.jp.

### Author Contributions

<sup>†</sup>C.K. and K.A. contributed equally.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This research was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI).

## ■ REFERENCES

- (1) (a) Kane, P. M.; Yamashiro, C. T.; Wolczyk, D. F.; Neff, N.; Goebel, M.; Stevens, T. H. *Science* **1990**, *250*, 651–657. (b) Hirata, R.; Ohsumi, Y.; Nakano, A.; Kawasaki, H.; Suzuki, K.; Anraku, Y. *J. Biol. Chem.* **1990**, *265*, 6726–6733.
- (2) Perler, F. B. *Nucleic Acids Res.* **2002**, *30*, 383–384.
- (3) (a) Noren, C.; Wang, J.; Perler, F. *Angew. Chem., Int. Ed.* **2000**, *39*, 450–466. (b) Paulus, H. *Annu. Rev. Biochem.* **2000**, *69*, 447–496. (c) Cheriyan, M.; Perler, F. B. *Adv. Drug Delivery Rev.* **2009**, *61*, 899–907.
- (4) (a) Ding, Y.; Xu, M.; Ghosh, I.; Chen, X.; Ferrandon, S.; Lesage, G.; Rao, Z. *J. Biol. Chem.* **2003**, *278*, 39133–39142. (b) Sun, P.; Ye, S.; Ferrandon, S.; Evans, T. C.; Xu, M. Q.; Rao, Z. *J. Mol. Biol.* **2005**, *353*, 1093–1105. (c) Liu, Z.; Frutos, S.; Bick, M. J.; Vila-Perelló, M.; Debelouchina, G. T.; Darst, S. a; Muir, T. W. *Proc. Natl. Acad. Sci. U. S. A.* **2014**, *111*, 8422–8427.
- (5) For a recent study of UV-induced bond cleavage of the peptide/protein backbone, see: (a) Bosques, C. J.; Imperiali, B. *J. Am. Chem. Soc.* **2003**, *125*, 7530–7531. (b) Endo, M.; Nakayama, K.; Kaida, Y.; Majima, T. *Angew. Chem., Int. Ed.* **2004**, *43*, 5643–5645. (c) Pellois, J.-P.; Muir, T. W. *Angew. Chem., Int. Ed.* **2005**, *44*, 5713–5717. (d) Toebe, M.; Coccoris, M.; Bins, A.; Rodenko, B.; Gomez, R.; Nieuwkoop, N. J.; van de Kastele, W.; Rimmelzwaan, G. F.; Haanen, J. B. A. G.; Ova, H.; Schumacher, T. N. M. *Nat. Med.* **2006**, *12*, 246–251. (e) Parker, L. L.; Kurutz, J. W.; Kent, S. B. H.; Kron, S. J. *Angew. Chem., Int. Ed.* **2006**, *45*, 6322–6325. (f) Li, H.; Hah, J.-M.; Lawrence, D. S. *J. Am. Chem. Soc.* **2008**, *130*, 10474–10475. (g) Celie, P. H. N.; Toebe, M.; Rodenko, B.; Ova, H.; Perrakis, A.; Schumacher, T. N. M. *J. Am. Chem. Soc.* **2009**, *131*, 12298–12304.
- (6) For recent study of UV-induced conformational change of the peptide/protein backbone, see: (a) Dos Santos, S.; Chandravarkar, A.; Mandal, B.; Mimna, R.; Murat, K.; Saucède, L.; Tella, P.; Tuchscherer, G.; Mutter, M. *J. Am. Chem. Soc.* **2005**, *127*, 11888–11889. (b) Taniguchi, A.; Skwarczynski, M.; Sohma, Y.; Okada, T.; Ikeda, K.; Prakash, H.; Mukai, H.; Hayashi, Y.; Kimura, T.; Hirota, S.; Matsuzaki, K.; Kiso, Y. *ChemBioChem* **2008**, *9*, 3055–3065. (c) Vila-Perelló, M.; Hori, Y.; Ribó, M.; Muir, T. W. *Angew. Chem., Int. Ed.* **2008**, *47*, 7764–7767. (d) Binschik, J.; Zettler, J.; Mootz, H. D. *Angew. Chem., Int. Ed.* **2011**, *50*, 3249–3252.
- (7) (a) Shigenaga, A.; Tsuji, D.; Nishioka, N.; Tsuda, S.; Itoh, K.; Otaka, A. *ChemBioChem* **2007**, *8*, 1929–1931. (b) Shigenaga, A.; Yamamoto, J.; Nishioka, N.; Otaka, A. *Tetrahedron* **2010**, *66*, 7367–7372. (c) Shigenaga, A.; Ogura, K.; Hirakawa, H.; Yamamoto, J.; Ebisuno, K.; Miyamoto, L.; Ishizawa, K.; Tsuchiya, K.; Otaka, A. *ChemBioChem* **2012**, *13*, 968–971. (d) Yamamoto, J.; Denda, M.; Maeda, N.; Kita, M.; Komiya, C.; Tanaka, T.; Nomura, W.; Tamamura, H.; Sato, Y.; Yamauchi, A.; Shigenaga, A.; Otaka, A. *Org. Biomol. Chem.*



- 2014, 12, 3821–3826. (e) Jung, D.; Sato, K.; Min, K.; Shigenaga, A.; Jung, J.; Otaka, A.; Kwon, Y. *Chem. Commun.* **2015**, 51, 9670–9673.
- (8) Milstien, S.; Cohen, L. A. *Proc. Natl. Acad. Sci. U. S. A.* **1970**, 67, 1143–1147.
- (9) Levine, M. N.; Raines, R. T. *Chem. Sci.* **2012**, 3, 2412–2420.
- (10) Matsumoto, H.; Sohma, Y.; Kimura, T.; Hayashi, Y.; Kiso, Y. *Bioorg. Med. Chem. Lett.* **2001**, 11, 605–609.
- (11) Beesley, R. M.; Ingold, C. K.; Thorpe, J. F. *J. Chem. Soc., Trans.* **1915**, 107, 1080–1106.
- (12) Jung, M. E.; Piizzi, G. *Chem. Rev.* **2005**, 105, 1735–1766.
- (13) Bachrach, S. M. *J. Org. Chem.* **2008**, 73, 2466–2468.
- (14) (a) Bochet, C. G. *J. Chem. Soc. Perkin Trans. 1* **2001**, 2, 125–142. (b) Brieke, C.; Rohrbach, F.; Gottschalk, A.; Mayer, G.; Heckel, A. *Angew. Chem., Int. Ed.* **2012**, 51, 8446–8476.
- (15) Warnecke, A.; Kratz, F. *J. Org. Chem.* **2008**, 73, 1546–1552.
- (16) Kawahata, N.; Weisberg, M.; Goodman, M. *J. Org. Chem.* **1999**, 64, 4362–4369.
- (17) (a) Packman, L. C. *Tetrahedron Lett.* **1995**, 36, 7523–7526. (b) Nicolás, E.; Pujades, M.; Bacardit, J.; Giral, E.; Albericio, F. *Tetrahedron Lett.* **1997**, 38, 2317–2320. (c) Zahariev, S.; Guarnaccia, C.; Pongor, C. I.; Quaroni, L.; Čemažar, M.; Pongor, S. *Tetrahedron Lett.* **2006**, 47, 4121–4124. (d) Subirós-Funosas, R.; El-Faham, A.; Albericio, F. *Tetrahedron* **2011**, 67, 8595–8606.
- (18) For details, see the [Experimental section](#).
- (19) Demmer, O.; Dijkgraaf, I.; Schumacher, U.; Marinelli, L.; Cosconati, S.; Gourni, E.; Wester, H. J.; Kessler, H. *J. Med. Chem.* **2011**, 54, 7648–7662.
- (20) We failed to collect the NMR chart of those compounds at higher temperature due to thermal decomposition.